Tags

Type your tag names separated by a space and hit enter

Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial.
Gastrointest Endosc 2017; 85(5):1005-1013GE

Abstract

BACKGROUND AND AIMS

Prospective data have shown the benefit of rectal indomethacin (IND) for preventing post-ERCP pancreatitis (PEP). A recent pilot study demonstrated a lower incidence of PEP after an 8-hour lactated Ringer's solution (LR) infusion. The aim of this study was to evaluate the efficacy of IND with or without bolus LR in patients at high-risk for PEP.

METHODS

In this randomized, double-blinded, placebo-controlled trial we assigned patients to standard normal saline solution (NS) + placebo, NS + IND, LR + placebo, or LR + IND. Each liter of fluid infusion was completed within 30 minutes. Patients were determined high-risk based established criterion and excluded if they had pancreatitis, contraindications to IND, or signs of volume overload. Our primary outcome was PEP, defined by standardized criterion. Our secondary outcomes were severe acute pancreatitis, localized adverse events, death, length of stay, and readmission.

RESULTS

Our sample consisted of 192 patients (48 per group) who completed follow-up at 24 hours and at 30 days post-ERCP. All patients had at least 1 high-risk criterion for PEP, and 56% had >1. PEP occurred in 3 patients (6%) in the LR + IND versus 10 (21%) in the NS + placebo group (P = .04). Readmission rates were lower in the LR + IND group (1 [2%]) versus the NS + placebo group (6 [13%]; P = .03). No differences were found between the other study groups. There was 1 case of severe pancreatitis (NS + IND) and 1 case of pseudocyst (LR + IND).

CONCLUSIONS

In patients at high risk for PEP, LR + IND reduced the incidence of PEP and readmission rates compared with NS + placebo. (Clinical trial registration number: NCT02641561.).

Authors+Show Affiliations

Cooper Medical School of Rowan University, MD Anderson Cancer Center at Cooper, Department of Medicine, Division of Gastroenterology and Liver Diseases, Mount Laurel, New Jersey, USA.Cooper Medical School of Rowan University, MD Anderson Cancer Center at Cooper, Department of Medicine, Division of Gastroenterology and Liver Diseases, Mount Laurel, New Jersey, USA.Cooper Medical School of Rowan University, MD Anderson Cancer Center at Cooper, Department of Medicine, Division of Gastroenterology and Liver Diseases, Mount Laurel, New Jersey, USA.Cooper Medical School of Rowan University, MD Anderson Cancer Center at Cooper, Department of Medicine, Division of Gastroenterology and Liver Diseases, Mount Laurel, New Jersey, USA.Cooper Medical School of Rowan University, MD Anderson Cancer Center at Cooper, Department of Medicine, Division of Gastroenterology and Liver Diseases, Mount Laurel, New Jersey, USA.Cooper Medical School of Rowan University, MD Anderson Cancer Center at Cooper, Department of Medicine, Division of Gastroenterology and Liver Diseases, Mount Laurel, New Jersey, USA.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27816497

Citation

Mok, Shaffer R S., et al. "Lactated Ringer's Solution in Combination With Rectal Indomethacin for Prevention of post-ERCP Pancreatitis and Readmission: a Prospective Randomized, Double-blinded, Placebo-controlled Trial." Gastrointestinal Endoscopy, vol. 85, no. 5, 2017, pp. 1005-1013.
Mok SRS, Ho HC, Shah P, et al. Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial. Gastrointest Endosc. 2017;85(5):1005-1013.
Mok, S. R. S., Ho, H. C., Shah, P., Patel, M., Gaughan, J. P., & Elfant, A. B. (2017). Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial. Gastrointestinal Endoscopy, 85(5), pp. 1005-1013. doi:10.1016/j.gie.2016.10.033.
Mok SRS, et al. Lactated Ringer's Solution in Combination With Rectal Indomethacin for Prevention of post-ERCP Pancreatitis and Readmission: a Prospective Randomized, Double-blinded, Placebo-controlled Trial. Gastrointest Endosc. 2017;85(5):1005-1013. PubMed PMID: 27816497.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial. AU - Mok,Shaffer R S, AU - Ho,Henry C, AU - Shah,Paurush, AU - Patel,Milan, AU - Gaughan,John P, AU - Elfant,Adam B, Y1 - 2016/11/02/ PY - 2016/07/26/received PY - 2016/10/24/accepted PY - 2016/11/7/pubmed PY - 2017/10/24/medline PY - 2016/11/7/entrez SP - 1005 EP - 1013 JF - Gastrointestinal endoscopy JO - Gastrointest. Endosc. VL - 85 IS - 5 N2 - BACKGROUND AND AIMS: Prospective data have shown the benefit of rectal indomethacin (IND) for preventing post-ERCP pancreatitis (PEP). A recent pilot study demonstrated a lower incidence of PEP after an 8-hour lactated Ringer's solution (LR) infusion. The aim of this study was to evaluate the efficacy of IND with or without bolus LR in patients at high-risk for PEP. METHODS: In this randomized, double-blinded, placebo-controlled trial we assigned patients to standard normal saline solution (NS) + placebo, NS + IND, LR + placebo, or LR + IND. Each liter of fluid infusion was completed within 30 minutes. Patients were determined high-risk based established criterion and excluded if they had pancreatitis, contraindications to IND, or signs of volume overload. Our primary outcome was PEP, defined by standardized criterion. Our secondary outcomes were severe acute pancreatitis, localized adverse events, death, length of stay, and readmission. RESULTS: Our sample consisted of 192 patients (48 per group) who completed follow-up at 24 hours and at 30 days post-ERCP. All patients had at least 1 high-risk criterion for PEP, and 56% had >1. PEP occurred in 3 patients (6%) in the LR + IND versus 10 (21%) in the NS + placebo group (P = .04). Readmission rates were lower in the LR + IND group (1 [2%]) versus the NS + placebo group (6 [13%]; P = .03). No differences were found between the other study groups. There was 1 case of severe pancreatitis (NS + IND) and 1 case of pseudocyst (LR + IND). CONCLUSIONS: In patients at high risk for PEP, LR + IND reduced the incidence of PEP and readmission rates compared with NS + placebo. (Clinical trial registration number: NCT02641561.). SN - 1097-6779 UR - https://www.unboundmedicine.com/medline/citation/27816497/Lactated_Ringer's_solution_in_combination_with_rectal_indomethacin_for_prevention_of_post_ERCP_pancreatitis_and_readmission:_a_prospective_randomized_double_blinded_placebo_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016-5107(16)30720-9 DB - PRIME DP - Unbound Medicine ER -